Juliana Gomez Abanto, MD
Neurology · Fort Myers, FLNPI 1770036881
Payments from drug & device makers
Across 121 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$468
- EMD Serono, Inc.$318
- UCB, Inc.$288
- Lilly USA, LLC$194
- Pfizer$126
- Teva Pharmaceuticals USA, Inc.$123
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,77594%
- Education$1365%
- Gifts$462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $468 |
| EMD Serono, Inc. | 7 | $318 |
| UCB, Inc. | 13 | $288 |
| Lilly USA, LLC | 11 | $194 |
| Pfizer | 7 | $126 |
| Teva Pharmaceuticals USA, Inc. | 2 | $123 |
| SK Life Science, Inc. | 5 | $114 |
| Novartis | 6 | $108 |
| Argenx US, Inc. | 4 | $107 |
| Genentech USA, Inc. | 4 | $107 |
| Bristol Myers Squibb | 1 | $93 |
| AstraZeneca | 4 | $84 |
| Neurocrine Biosciences, Inc. | 3 | $80 |
| Amgen | 3 | $76 |
| CSL Behring | 2 | $70 |
| Acadia Pharmaceuticals Inc | 3 | $57 |
| Lundbeck LLC | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Eisai Inc. | 3 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Chiesi USA, Inc. | 1 | $46 |
| Merz Pharmaceuticals, LLC | 2 | $36 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Neurelis, Inc. | 1 | $30 |
| Sanofi | 1 | $26 |
| Banner Life Sciences, LLC | 1 | $23 |
| Livanova USA, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| TG Therapeutics, Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $15 |
How this compares
$2,956 in reported general payments places this provider in the 50th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 53 | $578,343 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $194,878 |
| NuplazidPimavanserin Tartrate | 34 | $156,205 |
| Nurtec OdtRimegepant Sulfate | 91 | $125,369 |
| VumerityDiroximel Fumarate | 12 | $120,106 |
| Emgality PenGalcanezumab-Gnlm | 145 | $114,981 |
| IngrezzaValbenazine Tosylate | 12 | $97,523 |
| UbrelvyUbrogepant | 65 | $90,986 |
| Aimovig AutoinjectorErenumab-Aooe | 86 | $70,234 |
| NourianzIstradefylline | 20 | $56,233 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 43 | $43,044 |
| GocovriAmantadine Hcl | 12 | $40,712 |
| GlatopaGlatiramer Acetate | 17 | $40,600 |
| QuliptaAtogepant | 31 | $33,693 |
| Emgality SyringeGalcanezumab-Gnlm | 25 | $30,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $57 | $156,20534 claims |
| AbbVieUbrelvy, Qulipta, Botox | $468 | $138,864107 claims |
| PfizerNurtec Odt, Eliquis | $126 | $137,834107 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $80 | $97,52312 claims |
| Kyowa Kirin, Inc.Nourianz | $36 | $56,23320 claims |
| Lilly USA, LLCReyvow | $194 | $23,04131 claims |
| UCB, Inc.Briviact | $288 | $19,87714 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $49 | $1,28815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,434 neurology providers in Florida.
Other neurology in Fort Myers
- Wendy BondFort Myers$14.7M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.